Anselacox

Etoricoxib has been approved in Europe, Latin America, and Asia-Pacific region for the treatment of

• • -Acute Gouty Arthritis.

• • (RA),
    -Ankylosing Spondylitis (AS),
    

• • -Chronic Musculoskeletal Pain,
    -Rheumatoid Arthritis

• • Osteoarthritis (OA),
    -Acute Pain,Post operative pain,
    

  
  

EMA mean

•  European Medicines Agency

• European Medical America

• European mixed America

this study was carried out to investigate the bioequivalence of Anselacox 90mg FC Tablets, made by EVA Pharma and Arcoxia 90mg FC Tablets

• Bioequivalence of Anselacox 30mg FC Tablets

  
  

• Bioequivalence of Anselacox 120mg FC Tablets

  
  

• Bioequivalence of Anselacox 90mg FC Tablets

  
  

• Bioequivalence of Anselacox 60mg FC Tablets

  
  

Contraindications of Anselacox.

•  Patients with hypertension whose blood pressure is persistently elevated above 140/90

•  Established ischaemic heart disease, 

  
  

• Diabetic patients

•  • Children and adolescents under 16 years of age

There are...............................

• 30,60,90,120mg

• 60,90,120

• 30&60&120&180mg

• 30&60 mg

The more selective …. The more ....................

• used

• useful

• effective

• Faster

pain is

• An unpleasant sensory and emotional experience

• A pleasant sensory and emotional experience

• An unpleasant sensory ONLY

• An unpleasant emotional experience

The study (clbp )compare diclophinac 150 with Anselacox ..............mg

• 120

• 60

• 90

• 30

Mechanism of Action of NSAIDs

• Selective COX-2 Inhibitor

• Non selective NSAiD

• Selective COX-1 Inhibitor

• Selective COX-2 &COX -1 Inhibitor

Type of population used in study compare celoxibe vs Anselacox

• Gouty Arthritis

• Rheumatoid Arthritis

• Osteoarthritis patients

• Chronic low back pain